Abstract
The in vitro screening of small molecules for enzymatic inhibition provides an efficient means of finding new compounds for developing drug candidates. This strategy has the advantage of being rapid and inexpensive to perform. Enzymes are suitable targets for screening when simple methods to obtain them and measure their activities are available and there is evidence of their essential role in the parasite’s life cycle. Here, we describe the screening of small molecules as inhibitors of two Fasciola hepatica enzyme targets (cathepsin L and triose phosphate isomerase), an initial step to find new potential compounds for drug development strategies.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Brennan GP, Fairweather I, Trudgett A, Hoey EM, McCoy M, McConville M et al (2007) Understanding triclabendazole resistance. Exp Mol Pathol 82:104–109
Boray J, Crowfoot P, Strong M, Allison J, Schellenbaum M, von Orelli M et al (1983) Treatment of immature and mature Fasciola hepatica infections in sheep with triclabendazole. Vet Rec 113:315–317
Kelley JM, Elliott TP, Beddoe T, Anderson G, Skuce P, Spithill TW (2016) Current threat of Triclabendazole resistance in Fasciola hepatica. Trends Parasitol 32(6):458–469
Copeland R (2013) Evaluation of enzyme inhibitors in drug discovery. In: A guide for medicinal chemists and pharmacologists, 2nd edn. John Wiley & Sons, Inc., Hoboken, New Jersey
Baker NC, Ekins S, Williams AJ, Tropsha A (2018) A bibliometric review of drug repurposing. Drug Discov Today 23(3):661–672
Cancela M, Acosta D, Rinaldi G, Silva E, Durán R, Roche L et al (2008) A distinctive repertoire of cathepsins is expressed by juvenile invasive Fasciola hepatica. Biochimie 10:1461–1475
Robinson MW, Tort JF, Lowther J, Donnelly SM, Wong E, Xu W et al (2008) Proteomics and phylogenetic analysis of the cathepsin L protease family of the helminth pathogen Fasciola hepatica: expansion of a repertoire of virulence associated factors. Mol Cell Proteomics 6:1111–1123
McGonigle L, Mousley A, Marks NJ, Brennan GP, Dalton JP, Spithill TW et al (2008) The silencing of cysteine proteases in Fasciola hepatica newly excysted juveniles using RNA interference reduces gut penetration. Int J Parasitol 38(2):149–750
Corvo I, Cancela M, Cappetta M, Pi-Denis N, Tort JF, Roche L (2009) The major cathepsin L secreted by the invasive juvenile Fasciola hepatica prefers proline in the S2 subsite and can cleave collagen. Mol Biochem Parasitol 167(1):41–47
Lowther J, Robinson MW, Donnelly SM, Xu W, Stack CM, Matthews JM, Dalton JP (2009) The importance of pH in regulating the function of the Fasciola hepatica cathepsin L1 cysteine protease. PLoS Negl Trop Dis 3(1):e369
Donnelly S, O’Neill SM, Stack CM, Robinson MW, Turnbull L, Whitchurch C, Dalton JP (2010) Helminth cysteine proteases inhibit TRIF -dependent activation of macrophages via degradation of TLR3. J Biol Chem 285(5):3383–3392
Robinson MW, Dalton JP, O’Brien BA, Donnelly S (2013) Fasciola hepatica: the therapeutic potential of a worm secretome. Int J Parasitol 43(3-4):283–291
Zinsser VL, Hoey EM, Trudgett A, Timson DJ (2013) Biochemical characterisation of triose phosphate isomerase from the liver fluke Fasciola hepatica. Biochimie 95:2182–2189
Olivares-Illana V, Perez-Montfort R, Lopez-Calahorra F, Costas M, Rodriguez-Romero A, Tuena de Gomez-Puyou M (2006) Structural differences in triosephosphate isomerase from different species and discovery of a multitrypanosomatid inhibitor. Biochemistry 45:2556–2560
Enriquez-Flores S, Rodriguez-Romero A, Hernandez-Alcantara G, De la Mora-De la Mora I, Gutierrez-Castrellon P et al (2008) Species-specific inhibition of Giardia lamblia triosephosphate isomerase by localized perturbation of the homodimer. Mol Biochem Parasitol 157:179–186
Alvarez G, Aguirre-López B, Varela J, Cabrera M, Merlino A, López GV et al (2010) Massive screening yields novel and selective triosephosphate isomerase dimer-interface-irreversible inhibitors with anti-trypanosomal activity. Eur J Med Chem 45:5767–5772
Ferraro F, Merlino A, Dell Oca N, Gil J, Tort JF, Gonzalez M et al (2016) Identification of Chalcones as Fasciola hepatica Cathepsin L inhibitors using a comprehensive experimental and computational approach. PLoS Negl Trop Dis 10(7):e0004834
Cabrera M, Simoens M, Falchi G, Lavaggi ML, Piro OE, Castellano EE et al (2007) Synthetic chalcones, flavanones, and flavones as antitumoral agents: biological evaluation and structure-activity relationships. Bioorg Med Chem 15(10):3356–3367
Rzychon M, Chmiel D, Stec-Niemczyk J (2004) Modes of inhibition of cysteine proteases. Acta Biochim Pol 51(4):861–873
Acknowledgments
This work was supported by Universidad de la República and PEDECIBA, Uruguay and the Science and Innovation Fund, Uruguay—United Kingdom (British Embassy Montevideo, Grant SPF.2014.F001).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Ferraro, F., Cabrera, M.A., Álvarez, G.I., Corvo, I. (2020). Drug Targets: Screening for Small Molecules that Inhibit Fasciola hepatica Enzymes. In: Cancela, M., Maggioli, G. (eds) Fasciola hepatica. Methods in Molecular Biology, vol 2137. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-0475-5_17
Download citation
DOI: https://doi.org/10.1007/978-1-0716-0475-5_17
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-0474-8
Online ISBN: 978-1-0716-0475-5
eBook Packages: Springer Protocols